Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Literature
1.
Chatziralli I, Theodossiadis G, Moschos MM, Mitropoulos P, Theodossiadis P (2017) Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data. Graefes Arch Clin Exp Ophthalmol. doi:10.​1007/​s00417-017-3613-1
2.
Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMed
3.
Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRef
4.
Papadopoulos N, Martin J, Ruan Q, Rafique A (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentral
5.
Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31:357–362CrossRefPubMed
6.
Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and chorodial tissues of monkey eyes. Br J Ophthalmol 98:813–825CrossRefPubMed
7.
Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase lll study. Ophthalmology 118:2041–2049CrossRefPubMed
8.
Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sanbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the Copernicus study. Ophthalmology 121:1414–1420CrossRefPubMed
9.
Ogura Y, Roider J, Korobelnik JF, Holtz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, Galileo study group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 158:1032–1038CrossRefPubMed
10.
Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMed
Metadata
Title
Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data
Authors
Dan Călugăru
Mihai Călugăru
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3681-2

Other articles of this Issue 7/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2017 Go to the issue

Letter to the Editor (by invitation)

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion

Pediatrics

Macular morphology in former preterm and full-term infants aged 4 to 10 years

Cornea

Descemet membrane endothelial keratoplasty (DMEK) early stage graft failure in eyes with preexisting glaucoma

Retinal Disorders

Massive subretinal and subretinal pigment epithelial hemorrhage displacement with perfluorocarbon liquid using a two-step vitrectomy technique

Review Article

Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases

Retinal Disorders

Retinal vascular changes after vitrectomy for idiopathic epiretinal membrane: a pilot study with dynamic vessel analysis